Pfizer Inc. (NYSE:PFE) Holdings Boosted by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. grew its holdings in Pfizer Inc. (NYSE:PFE) by 9.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 636,215 shares of the biopharmaceutical company’s stock after purchasing an additional 54,844 shares during the period. Oppenheimer & Co. Inc.’s holdings in Pfizer were worth $16,122,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Rialto Wealth Management LLC purchased a new position in Pfizer during the 4th quarter valued at about $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $27,000. Gould Capital LLC grew its position in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the 4th quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer in the 4th quarter valued at approximately $30,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on PFE shares. UBS Group lifted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Cantor Fitzgerald started coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective for the company. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Stock Performance

Shares of NYSE PFE opened at $23.97 on Monday. The business’s 50-day simple moving average is $23.26 and its 200-day simple moving average is $24.89. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The firm has a market cap of $136.27 billion, a price-to-earnings ratio of 17.37, a P/E/G ratio of 0.87 and a beta of 0.57.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter last year, the company posted $0.82 earnings per share. The company’s revenue for the quarter was down 7.8% compared to the same quarter last year. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.18%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer’s dividend payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.